Elucidation of the Gemcitabine Transporters of Escherichia coli K-12 and Gamma-Proteobacteria Linked to Gemcitabine-Related Chemoresistance

Nikoleta Iosifidou,Eleni Anagnostopoulou,Maria Botou,Eirini Kalfa,Ekaterini Tatsaki,Stathis Frillingos

DOI: https://doi.org/10.3390/ijms25137012

IF: 5.6

2024-06-27

International Journal of Molecular Sciences

Abstract:Gemcitabine (2′,2′-difluoro-2′-deoxycytidine), a widely used anticancer drug, is considered a gold standard in treating aggressive pancreatic cancers. Gamma-proteobacteria that colonize the pancreatic tumors contribute to chemoresistance against gemcitabine by metabolizing the drug to a less active and deaminated form. The gemcitabine transporters of these bacteria are unknown to date. Furthermore, there is no complete knowledge of the gemcitabine transporters in Escherichia coli or any other related proteobacteria. In this study, we investigate the complement of gemcitabine transporters in E. coli K-12 and two common chemoresistance-related bacteria (Klebsiella pneumoniae and Citrobacter freundii). We found that E. coli K-12 has two high-affinity gemcitabine transporters with distinct specificity properties, namely, NupC and NupG, whereas the gemcitabine transporters of C. freundii and K. pneumoniae include the NupC and NupG orthologs, functionally indistinguishable from their counterparts, and, in K. pneumoniae, one additional NupC variant, designated KpNupC2. All these bacterial transporters have a higher affinity for gemcitabine than their human counterparts. The highest affinity (KM 2.5–3.0 μΜ) is exhibited by NupGs of the bacteria-specific nucleoside-H+ symporter (NHS) family followed by NupCs (KM 10–13 μΜ) of the concentrative nucleoside transporter (CNT) family, 15–100 times higher than the affinities reported for the human gemcitabine transporter hENT1/SLC29A1, which is primarily associated with gemcitabine uptake in the pancreatic adenocarcinoma cells. Our results offer a basis for further insight into the role of specific bacteria in drug availability within tumors and for understanding the structure–function differences of bacterial and human drug transporters.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The problem this paper attempts to address is: elucidating the gemcitabine transport proteins in Escherichia coli K-12 and Gamma-Proteobacteria, which are associated with gemcitabine-related chemotherapy resistance.

Specifically, the paper focuses on the following aspects:

1. **Identification of gemcitabine transport proteins**: It is currently unclear which transport proteins are responsible for gemcitabine transport in Escherichia coli K-12 and other related Gamma-Proteobacteria. The researchers aim to identify these transport proteins to understand how they affect the metabolism and transport of gemcitabine.

2. **Mechanisms of chemotherapy resistance**: Gemcitabine is a commonly used anticancer drug, particularly in the treatment of pancreatic cancer. However, bacteria in the tumor microenvironment can enhance chemotherapy resistance by metabolizing gemcitabine. By identifying these transport proteins, the researchers hope to further understand the role of bacteria in chemotherapy resistance.

3. **Functional characteristics of transport proteins**: The researchers also aim to explore the functional characteristics of these transport proteins, including their affinity and specificity for gemcitabine, as well as their competitive relationships with other nucleoside analogs. This helps to understand the structural and functional differences between bacterial and human transport proteins.

Through these studies, the paper aims to provide a basis for understanding the role of specific bacteria in drug availability within tumors and to provide a foundation for further research on the structural-functional differences between bacterial and human drug transport proteins.